Impact of Vitamin D on 25-hydroxyvitamin D Levels and Physical Function
The Impact of Supplemental Vitamin D on Serum 25-hydroxyvitamin D Levels and Short Term Indicators of Physical Function
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and postmenopausal women age 60 years and older
- Women must be at least 1 year since last menses.
- Subjects must agree not to take their own vitamin D in amounts >600 IU/day (for ages 51-70 years) or >800 IU/day (for ages 71 - 80 years) or more than 600 mg/day of supplemental calcium.
- Subjects must agree not to have had more than 30 minutes/day of sun exposure at a southern latitude (< 34 degrees N) in the 2-month period prior to screening and not to travel south and be exposed to sunshine in the 3-month period prior to their final visit.
- They will agree not to use tanning salons during the study.
- Screening serum 25OHD of 20 to 50 nmol/L (8.0 to 20 ng/ml).
Exclusion Criteria:
- Kidney stones - in the last 3 years
- Calculated glomerular filtration rate < 30 ml/min
- Screening fasting spot urinary calcium:creatinine ratio (Ca:Cr) > 0.325 (corresponding to a 24-hr urine calcium of 350 mg)
- Serum calcium exceeding upper normal limit (reference range 8.3 -10.2 mg/dl)
- Other abnormalities in screening labs, at the discretion of the study physician (PI)
- Sarcoidosis
- Evidence of chronic liver disease, including alcoholism
- Cancer treatment in the last year (except basal cell carcinoma) or terminal illness
- Treatment in the last 6 months with estrogen, raloxifene, calcitonin, or testosterone (vaginal estrogen use okay)
- High dose thiazide therapy (>37.5 mg).
- Treatment in the last year with teriparatide or denosumab
- Treatment in the lsat 2 years with bisphosphonates
- Oral corticosteroid therapy for over 3 weeks within the last 6 months
- Anticonvulsant therapy
- Physical conditions such as osteoarthritis, rheumatoid arthritis, heart failure or hemiplegia severe enough to prevent reasonable physical activity.
- Non-English speaking subjects (We can't be confident that non-English speaking subjects could accurately identify intakes of calcium and vitamin D from non-study sources and this could increase their risk of toxicity from study drug.
- Other abnormalities in screening labs, at the discretion of the study physician (the PI)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: vitamin D3
Vitamin D3, 800 IU will be given initially; after 4 months if D level < 70 nmol/L, increase dose to 1600 IU for remainder of study.
|
Dose for intervention arm is 800 IU/day for first 4 months.
At 4 months, if vitamin D level <70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
Other Names:
|
|
Placebo Comparator: Placebo
Placebo, microcrystalline cellulose
|
Those in the placebo group will receive 1 capsule for first 4 months.
At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The effect of supplemental vitamin D3 vs placebo on leg power and nitrogen excretion.
Time Frame: 12 months
|
Aim of the study is to look at the effect of supplemental vitamin D3 vs placebo on leg power and nitrogen excretion.To determine Vitamin D will improve leg power and reduce muscle wasting, as measured by 24-hr nitrogen excretion.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To describe the safety (assessed by serum calcium) of the administered doses of vitamin D3.
Time Frame: 12 months
|
To describe the safety (assessed by serum calcium) of the administered doses of vitamin D3.
|
12 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To determine the effect of supplemental vitamin D3 vs placebo on SPPB.
Time Frame: 12 months
|
To determine the effect of supplemental vitamin D3 vs placebo on SPPB.
|
12 months
|
|
To determine the effect of supplemental vitamin D3 vs placebo on handgrip.
Time Frame: 12 months
|
To determine the effect of supplemental vitamin D3 vs placebo on handgrip.
|
12 months
|
|
To determine the effect of supplemental vitamin D3 vs placebo on stair climb.
Time Frame: 12 months
|
To determine the effect of supplemental vitamin D3 vs placebo on stair climb.
|
12 months
|
|
To determine the effect of supplemental vitamin D3 vs placebo on backward walking.
Time Frame: 12 months
|
To determine the effect of supplemental vitamin D3 vs placebo on backward walking.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bess Dawson-Hughes, MD, Tufts Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Nutrition Disorders
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Muscular Atrophy
- Atrophy
- Vitamin D Deficiency
- Sarcopenia
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
Other Study ID Numbers
- 2710 (CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.